Literature DB >> 11246535

Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors.

C Escuriola Ettingshausen1, S Halimeh, K Kurnik, R Schobess, C Wermes, R Junker, W Kreuz, H Pollmann, U Nowak-Göttl.   

Abstract

It has been recently suggested that the clinical phenotype of severe hemophilia A (HA) is influenced by co-inheritance with the factor V G1691A mutation. We therefore investigated 124 pediatric PUP patients with hemophilia (A: n = 111) consecutively admitted to German pediatric hemophilia treatment centers. In addition to factor VIII activity, the factor V (FV) G1691A mutation, the prothrombin (PT) G20210A variant, antithrombin, protein C, protein S and antithrombin were investigated. 92 out of 111 HA patients (F VIII activity < 1%) were suffering from severe HA. The prevalence of prothrombotic risk factors in children with severe HA was no different from previously reported data: FV G1691A 6.5%, PT G20201A 3.2%, and protein C type I deficiency 1.1%. No deficiency states of antithrombin or protein S were found in this cohort of hemophilic patients. The first symptomatic bleeding leading to diagnosis of severe hemophilia (< 1%) occurred with a median (range) age of 1.6 years (0.5-7.1) in children carrying defects within the protein C pathway or the PT gene mutation compared with non-carriers of prothrombotic risk factors (0.9 years (0.1-4.0; p = 0.01). The cumulative event-free bleeding survival was significantly prolonged in children carrying additionally prothrombotic defects (log-rank/Mantel-Cox: p = 0.0098). In conclusion, data of this multicenter cohort study clearly demonstrate that the first symptomatic bleeding onset in children with severe HA carrying prothrombotic risk factors is significantly later in life than in non-carriers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246535

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

Review 1.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

2.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

3.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

Review 4.  Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project.

Authors:  B A Konkle; J M Johnsen; M Wheeler; C Watson; M Skinner; G F Pierce
Journal:  Haemophilia       Date:  2018-05       Impact factor: 4.287

5.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

6.  Design and characterization of an APC-specific serpin for the treatment of hemophilia.

Authors:  Stéphanie G I Polderdijk; Ty E Adams; Lacramioara Ivanciu; Rodney M Camire; Trevor P Baglin; James A Huntington
Journal:  Blood       Date:  2016-10-27       Impact factor: 22.113

7.  New treatments in hemophilia: insights for the clinician.

Authors:  Karin Knobe; Erik Berntorp
Journal:  Ther Adv Hematol       Date:  2012-06

8.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

9.  Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Authors:  Beth Boulden Warren; Linda Jacobson; Christine Kempton; George R Buchanan; Michael Recht; Deborah Brown; Cindy Leissinger; Amy D Shapiro; Thomas C Abshire; Marilyn J Manco-Johnson
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.263

10.  Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.

Authors:  Susan Halimeh; Christoph Bidlingmaier; Christine Heller; Sven Gutsche; Susanne Holzhauer; Gili Kenet; Karin Kurnik; Daniela Manner; Alfonso Iorio; Ulrike Nowak-Göttl
Journal:  Biomed Res Int       Date:  2013-10-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.